GLP-1 and GIP may sound like complicated biology. They are natural signalling hormones involved in the body’s response to food. Medicines act on their receptors. Understanding the basics helps explain changes in appetite and blood glucose without turning a mechanism into a promise for every weight problem.
From eating to signalling
A meal sets off more than the digestion of nutrients. Signals travel between organs including the gut, pancreas and brain. GLP-1 and GIP are among the hormones involved. They are called incretins because they participate in the insulin response to eating.
Imagine a receptor as a receiving point. A suitable messenger can activate a signal there. A receptor agonist is a substance that activates that receiving point. This picture explains the basic idea but simplifies many interacting processes in the body.
Why appetite and glucose appear together
GLP-1-based medicines can support food-related insulin secretion. Blood glucose control is therefore an important treatment goal for people with type 2 diabetes. Appetite, hunger and fullness also matter when these medicines are used for weight management.
Having less appetite does not mean your body has stopped needing nutrients. If familiar portions become difficult, you may need to arrange meals differently. The useful question is not only how little you can eat, but how you can continue to nourish yourself adequately.
What GIP means for tirzepatide
Semaglutide, the active ingredient in Wegovy, activates GLP-1 receptors. Tirzepatide, the active ingredient in Mounjaro, activates both GIP and GLP-1 receptors. This explains the description “dual agonist”. It does not make the medicines interchangeable versions of one product.
Acting at two receptors does not automatically mean twice the weight loss or twice the safety. Clinical trials investigate outcomes. Individual selection also involves existing conditions, tolerability, other medicines and the practical requirements of treatment.
Why digestion belongs in the discussion
These medicines can affect stomach emptying. Symptoms such as nausea, vomiting or constipation therefore belong in preparation and follow-up conversations. However, a mechanism cannot explain every new abdominal symptom. Severity, duration and accompanying symptoms all matter.
Tell the team before surgery or deep sedation that you use the medicine. Do not create your own treatment break from this information. Persistent severe abdominal pain or ongoing vomiting should not be dismissed as simply proof that the medicine is working.
What the mechanism cannot establish
A food that affects natural hormone signals is not equivalent to a tested prescription medicine. Equally, a medicine does not replace adequate meals, activity or support. A phrase such as “natural GLP-1” says little on its own about a demonstrated benefit.
When assessing advertising, separate three questions. What biological explanation is being offered? What clinical evidence exists for this particular product? Which findings apply to people in circumstances like yours? An attractive diagram or scientific-sounding term cannot answer these questions by itself.
Common questions
Is GLP-1 a medicine?
GLP-1 is originally the name of a natural hormone. People also use the term informally for medicines acting at its receptor. The actual active ingredient and product name still matter.
Can hunger tell me whether treatment is working correctly?
Hunger alone is not enough to assess treatment. Discuss nutrition, symptoms, health goals and progress as well. Do not change your treatment based on how one particular day feels.
Sources & further reading
- EMA: Wegovy – EPAR und Produktinformation
- EMA: Mounjaro – EPAR und Produktinformation
- WHO: GLP-1 therapies for obesity, 1 December 2025
Sources checked:
Questions and experiences
Share a question or a useful experience about this topic. Every contribution is checked before publication. Comments may be written in different languages.
Loading reader contributions…
Opening the form sets a necessary session cookie. No email address is required. Publication is subject to moderation and is not guaranteed. For deletion requests: Contact